Introduction {#Sec1}
============

Chronic obstructive pulmonary disease (COPD) is a progressive life-threatening disease that is significantly increasing in prevalence. The World Health Organization (WHO) predicts that COPD will become the third leading cause of death worldwide by 2030 \[[@CR1]--[@CR3]\]. There is currently no cure for this disease, and smoking cessation remains the most prominent intervention \[[@CR4]\]. Because of the lack of effective curative pharmaceutical options and the increase in prevalence, extensive efforts have been devoted to the development of new strategies for cell replacement and tissue remodeling in COPD. So far, most focus has been on mesenchymal stromal cell (MSC) therapy. MSC are theoretically ideal candidates for cell therapeutic approaches because of their low or absent constitutive HLA class I and II expression, allowing allogeneic administration of MSCs obtained from normal healthy volunteers, and their immunosuppressive and antibacterial properties \[[@CR5], [@CR6]\]. In this chapter, we will examine in detail the biological rationale for use of MSCs in COPD, clinical trials, and the current challenges for implementing this approach as a potential therapy for COPD.

COPD---A Heterogeneous Lung Disease with No Curative Treatment Available {#Sec2}
========================================================================

COPD is a progressive lower respiratory condition, which has a massive impact on public health worldwide. Increasing in prevalence, COPD is currently responsible for over 120,000 US deaths annually and is expected to become the third leading cause of death globally in the next few years \[[@CR7]\]. COPD is most often associated with long-term smokers over the age of 40 and is thought to be driven by abnormal tissue response(s) to inhaled toxic particles over time. The life expectancy of continuous cigarette smokers is at least 10 years shorter than nonsmokers and the absolute risk of developing COPD among this population has been estimated to be 15--30% \[[@CR8]\]; however, there is evidence for significant underdiagnosis \[[@CR9], [@CR10]\]. The most common symptoms of COPD are chronic bronchitis (persistent cough with chronic mucus production), dyspnea (shortness-of-breath), wheezing, and chest tightness. As a progressive disease, these symptoms get worse over time. Current treatments, most importantly smoking cessation, are part of a delay strategy to slow down the physiological disease progression. These physiologic changes all contribute to the impairment of efficient breathing and include: the gradual loss-of-elasticity of the lung tissue leading to collapse of airway and alveolar sacs, weakening-to-rupture of alveolar septal walls, enlargement of segmented airspace, loss of gas-exchange surface area, increased mucus production, airway plugging, and airway narrowing driven by swelling and fibrosis (Fig. [6.1](#Fig1){ref-type="fig"}). COPD is a complex pathology with a diverse spectrum of clinical phenotypes, comorbidities, and treatment profiles \[[@CR11], [@CR12]\]. The GOLD criteria have been widely utilized to help standardize the COPD definitions and treatment guidelines; however, they do not fully encompass the diversity of COPD phenotypes \[[@CR13], [@CR14]\].Fig. 6.1Photomicrographs of lung tissue obtained from healthy and chronic obstructive pulmonary disease (COPD) subjects stained with hematoxylin-eosin. Arrows indicate alveolar space (side-to-side alveolar wall distance). Scale bars at 4× magnification represent 500 μm and at 10× magnification 200 μm

The treatments available to patients diagnosed with COPD are not curative and cannot completely stop disease progression; however, they are key to slowing disease progression and importantly to improve quality of life. The most important intervention at any stage is the cessation of smoking and/or limitation of exposure to other identified environmental risk factors. Symptomatic treatment throughout disease progression often relies on bronchodilators, which are inhaled beta-agonists or muscarinic antagonists. Early-stage individuals will most often be treated with short-acting bronchodilator therapies (SABA/SAMA); however, as the disease progresses treatment will need to incorporate long-acting drugs that affect these receptors (LABA/LAMA). Unfortunately, bronchodilators can only partially resolve lung hyperinflation in emphysema \[[@CR15]\], becomingly increasingly less effective as the disease progresses. Inhaled corticosteroids (ICS), often used to treat acute respiratory exacerbations, work by interfering with the transcription pathways of key inflammation genes; however, this treatment does not always work and unfortunately can have little to no long-term benefits \[[@CR16]\].

In addition to direct toxic effects of cigarette smoke on lung epithelial cells, there is increasing appreciation that altered or aberrant immune cell signaling significantly contributes to much of the irreparable tissue damage. Smokers with undiagnosed COPD normally experience low-level infiltration of inflammatory cells into the large airways and peripheral lung parenchyma and have what is increasingly recognized as early disease. In individuals with diagnosed COPD, the inflammatory process is amplified and prolonged leading to many of the tissue-remodeling events associated with chronic bronchitis and emphysema; hallmarks of COPD \[[@CR17]\]. For example, in smoking-induced emphysema, chronically activated macrophages have been found to express upregulated levels of several proteinases and matrix metalloproteinases (MMPs) in both human smokers and in mouse models of cigarette exposure \[[@CR18]\]. Macrophages also play a crucial role in triggering the initial immune response in responding to smoking induced inflammation. Alveolar macrophages are usually in a quiescent state and actually work to suppress the adaptive immune system in the healthy lung; however, in chronic inflammatory situations alveolar macrophages are the main source of proinflammatory amplification and play a significant role in causing an influx of other immune cells \[[@CR19]\].

Ultimately, the disease progresses to a point where gas exchange is limited by the tissue damage and extent of hyperinflation. In many cases invasive surgical interventions are the only option; these include endobronchial valve insertion, bullectomy, lung volume reduction surgery, and lung transplantation \[[@CR20]\]. Lung volume reduction surgeries can successfully address some issues with hyperinflation in selected patients by returning some of the mechanical advantage of normal breathing. However, invasive surgeries are associated with high morbidity and operative mortality \[[@CR21]--[@CR23]\], especially in late-stage COPD patients who are often poor targets for surgical intervention. For some patients with end-stage COPD, lung transplantation is the only option. However, this approach offers its own unique challenges including rejection risk, requirement for immunosuppression, and the limited supply of donor lungs. While transplanted lungs can certainly facilitate better gas exchange than severe COPD lungs, the benefits are balanced by the risks, as the 5 years survival of transplant recipients is only around 50% \[[@CR24]--[@CR27]\]. At present, there are no true curative treatments that can stop the progression of COPD, thus new therapeutic strategies are needed. Advances in cell-based therapies provide a platform for development of new therapeutic approaches in COPD. At this moment, much focus has been given to MSC cell-based therapies, mainly because of their immunomodulatory properties.

MSC-Based Therapy in Human Clinical Trials of COPD and Emphysema {#Sec3}
================================================================

The promising results in animal models have translated into clinical trials for treatment of COPD and emphysema. Searching on the ClinicalTrials.gov database for trials listed through November 28 2018, using the keywords "COPD" and "stromal cell"; "COPD" and "mesenchymal stromal cell"; "COPD" and "mesenchymal stem cell"; "Emphysema" and "stromal cell"; "Emphysema" and "mesenchymal stromal cell"; and "Emphysema" and "mesenchymal stem cell", identified 18 studies of human clinical trials. So far, four of the studies have been completed and had their results published in the PubMed database, four are still in the process of recruiting patients, three of them are active but not recruiting patients, three have an unknown status, and four of them have been withdrawn \[[@CR28]\]. This section will be focusing on the clinical studies that have been completed and for which results have been published (Table [6.1](#Tab1){ref-type="table"}).Table 6.1Completed clinical trials investigating MSCs for COPD treatmentNCT numberStudy designNo. patientsRouteNo. of cellsFollow up (months)Primary outcomeCommentsNCT01110252Non-randomizedPhase IUnicenterSingle groupOpen label4IV1 × 10^8^/mL(30 mL total)12SafetyFVCFEV1VCBMMCNCT00683722RandomizedPhase IIMulticenterParallel assignmentPlacebo controlled62IV100 × 10^6^ BM-MSC/kg(four infusions total)24SafetyNCT01306513ProspectivePhase IUnicentricSingle groupOpen label10IV1--2 × 10^6^ BM-MSCs/kg(two infusions total)12SafetyTolerabilityPrior LVRSNCT01872624Non-randomizedParallel assignmentOpen label10IB10^8^ MSCs in 30 mL saline4SafetyAbsence of deficitsEBV insertion

In 2011, Ribeiro-Paes et al. conducted the first clinical investigation evaluating the safety of using bone marrow-derived mononuclear cells (BMMC) in four patients with advanced-stage COPD (NCT01110252). Autologous BMMC were collected after 3 days of granulocyte colony stimulating factor (G-CSF) stimulation, and BMMC were isolated using Ficoll-Hypaque Premium™. The cells were further resuspended in albumin saline solution (ASS) at a final concentration of 1 × 10^8^ mononuclear cells/mL, and intravenously administered directly to the patients without freezing or in vitro culture procedures. The patients were evaluated by several pulmonary function tests, including forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and partial pressure of carbon dioxide (PaCO~2~). \[[@CR29]\] Importantly, due to the small size of this study, lack of controls, and the lack of statistical analysis no clear conclusions can be drawn from these results. Furthermore, the cells used in this study were heterogeneous mononuclear cells isolated from bone marrow aspirates, and not MSCs, and therefore this study cannot be considered as the first MSC study for treatment of COPD patients.

In 2013, Weiss et al. performed a prospective, randomized, double-blind, placebo-controlled industry-sponsored trial evaluating the safety and the efficacy of intravenous allogeneic MSCs (NCT00683722). The study enrolled 62 patients (40--80 years of age), from six different centers, with moderate-to-severe COPD (GOLD II or III). The patients were randomized into two groups, where the first group received non-HLA-matched allogeneic MSCs and the second group received placebo (vehicle) treatment. MSCs were obtained from unrelated donors, expanded in vitro for a total of five passages in culture medium supplemented with 10% FBS followed by cryopreservation using human serum albumin and 10% DMSO. After thawing, MSCs or vehicles were systemically infused four times (at day 0, 30, 60, and 90) and the patients were followed for 2 years. The patients were evaluated by ECG, exacerbation records, FEV1, FVC, total lung capacity, dyspnea assessment (Borg scale), and 6-min walk test. Systemic inflammation was measured by circulating levels of inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, IL-10, and C-reactive protein (CRP). All 62 patients completed all four infusions, and 63% of the patients receiving MSC infusion and 84% of the patients in the placebo group completed the full protocol. The infusions were well tolerated and no severe or fatal adverse events were observed during the MSC or vehicle administration. No significant differences in FEV1, FVC, and total lung capacity were seen between the groups. Nor were differences in 6-min walk test or dyspnea assessment observed between the two groups. For most of the circulating inflammatory cytokines no significant differences were seen between the MSC-treated patients and the vehicle group. However, a decrease in the CRP level in patients treated with MSC compared to their baseline CRP levels was observed. The most important finding in this study was that MSC administration was safe in an older population of patients with moderate-to-severe COPD \[[@CR30]\].

Stolk et al. performed a Phase I, prospective, open-label study (NCT01306513) where they aimed to assess the safety and feasibility of intravenously infused bone marrow-derived MSCs for ten patients with severe emphysema that had serial lung volume reduction surgeries (LVRS). During the first LVRS bone marrow was aspirated. MSCs were isolated from the bone marrow aspirates and expanded in vitro (passage 1--3) followed by cryopreservation. At three and four weeks prior to the second LVRS, MSCs were intravenously administered to the patients at two different occasions. Spirometry, gas transfer, lung volumes, and lung densitometry were evaluated at baseline and at the 12 months follow-up. Seven patients completed the full protocol. Three patients were withdrawn from the study due to problem aspirating bone marrow, no MSC growth, or persistent air leak after the first LVRS. No toxicity after the MSC infusions was observed and the patients did not report any symptoms that were considered related to the treatment. At 12 months follow-up, a significant increase in FEV1 and body weight was observed compared to baseline levels. However, if changes in FEV1 and body weight was due to MSC administration or to the surgeries remain unknown, since this study protocol did not include a control group. Importantly, no signs of increased pulmonary fibrosis were observed when lung tissue was evaluated by both histology and CT-derived lung density \[[@CR31]\].

de Oliveira et al. combined MSC administration with one-way endobronchial valve (EBV) insertion \[[@CR32]\]. This study was a prospective, patient-blinded, placebo (vehicle)-controlled, phase I study on ten patients with advanced heterogeneous emphysema (NCT01872624). de Oliveira et al. aimed to investigate the safety of combining EBV insertion with intrabronchial MSC administration. The authors hypothesized that combining intrabronchial MSC administration with EBV would reduce the inflammation, a common side effect of EBV placement. This study, however, was not designed to investigate MSC as a treatment for COPD, but rather specifically to investigate if MSC treatment would enhance EBV placement by reducing the underlying inflammation. Therefore, the secondary aim was to investigate if MSC administration reduced the systemic inflammation. Mononuclear cells (MNCs) were isolated from 60 mL bone marrow aspirate collected from the iliac crest of a single healthy donor using density-gradient centrifugation. MNCs were cultured at a density of 1 × 10^5^ cells per cm^2^ in Iscove's Modified Dulbecco's Medium supplemented with 15% fetal bovine serum, penicillin, and streptomycin at 37 °C, 5% CO~2~ for generation of MSCs. MSCs were immunophenotyped and samples were taken for microbiological and cytogenetic testing. MSCs were harvested at passage three or four, diluted in saline solution, and placed in infusion bags. Right before EBV insertion 10^8^ MSCs (in 30 mL saline) were administered to five of ten patients using a video bronchoscope with a 2.8-mm instrument channel. The patients in the vehicle group received saline. In both groups, the infusions were performed in the region where the EBVs were supposed to be placed (the segmental or subsegmental bronchus of all branches of the target lobe). Immediately after the MSC administration or vehicle administration and EBV insertion, a chest radiograph was performed to confirm the EBV placement. For the following 2 days, the patients were evaluated for body temperature, blood pressure, oxygen saturation, heart, and respiratory rates. Arterial blood gas, complete blood count, urea, creatinine, glucose, and electrolytes were evaluated at day 0, 1, 7, 30, and 90. Chest CT scans were performed at day 0, 30, and 90. Circulating levels of inflammatory cytokines were assessed in serial blood samples obtained throughout the study period. Efficacy was evaluated as improvement from baseline in FEV1, FVC, FEV1/FVC, total lung capacity, single-breath carbon monoxide diffusing capacity, the body mass index, airway obstruction, dyspnea, exercise index, and health-related quality of life (St. George's Respiratory Questionnaire). All ten patients completed the full protocol. The MSC administration was well tolerated and all patients tolerated the EBV insertion but one, who developed pneumonia, pneumothorax, empyema, and respiratory failure. No severe adverse events were seen in the group receiving MSC, but 40% in the MSC group and 60% in the placebo group experienced adverse events during the study period, and importantly none of the adverse events was reported to be related to the MSC administration. No difference in toxicological or lung function parameters such as FEV1, FVC, and total lung capacity were observed between the groups. In accordance with data reported by Weiss et al. \[[@CR30]\] the MSC treated group had significantly reduced levels in CRP at day 30 and 90 post administration. Patients receiving MSC infusions were reported to have a significant decrease in the St. George's Respiratory Questionnaire scores compared to the placebo group at day 90 post administration. The authors concluded that intrabronchial MSC administration in combination with EBV insertion appears to be safe in patients with severe heterogeneous emphysema. Furthermore, in this study MSC administration tended towards decreased circulating CRP levels; however, due to the low number of recruited patients and the limited follow-up period it was not possible to evaluate if MSC treatment altered the efficiency of the EBV placement or the subsequent clinical COPD course. \[[@CR32]\].

Finally, Armitage et al. recently published a single site, phase I study that was not listed at the NIH ClinicalTrials.gov database, rather only in the Australian clinical trials registry (number 12614000731695), which aimed to investigate the distribution of intravenously infused MSCs into COPD patients. Nine patients with mild-to-severe COPD (GOLD I-IV) received infusion of low passage allogenic bone marrow-derived MSCs radiolabeled with indium-111, followed by a second infusion of unlabeled MSCs one week post the first administration. In similarity with the other clinical trials, all patients tolerated the MSC infusions well and no infusional or short-term adverse effects were reported. Following the first infusion, labeled MSCs were detected in the lungs within 30 min by computed tomography (CT) scan, and remained detectible 24 h after the infusion. After 24 h, indium-111 was detected in spleen, liver, and bone marrow up to 7 days after infusion. Moreover, 4 h after the first infusion the patients were assessed by single-photon emission computed tomography (SPECT) to evaluate MSC localization within the lungs. Furthermore, the amount of indium-111 positively correlated with the baseline FEV1 and the diffusing capacity of the lung for carbon monoxide. In addition, this study further aimed to investigate systemic inflammation following the MSC infusion. The authors were not able to detect IL-1 beta, IL-10, IL-12p70, or IL-17A; however, increased circulating levels of CRP were detected at 1 h and up to 2 days after MSC administration. Interestingly, this study suggests that MSC infusion shifted the balance towards a more anti-inflammatory profile, as the number of circulating regulatory T-cells were increased 7 days after MSC administration and the proportion of dendritic cells were altered, favoring plasmacytoid dendritic cells \[[@CR33]\].

Current clinical trials that aimed to evaluate the effect of MSC administration in COPD patients differ in a wide range of factors such as routes of administration, number of MSC administered, number of administrations, use of fresh MSCs or culture-expanded MSCs. Furthermore, all the investigations discussed above, were phase I-II studies that were underpowered in order to detect potential efficacy and no improved pulmonary function or respiratory quality of life was observed. Although the primary end-point was safety and all studies reported that MSC administration was well tolerated and no toxicity was observed, further studies, both clinical and preclinical, are needed to better understand potential therapeutic efficacy of MSCs in COPD.

The Hurdles That Need to Be Overcome {#Sec4}
====================================

Despite increasing number of preclinical studies demonstrating that MSC administration could prevent or treat experimental COPD and emphysema \[[@CR34]--[@CR50]\], clinical studies have not been able to reproduce the preclinical results, and to date no efficacy or significantly improved pulmonary function in COPD patients have been observed. In this section, we will be discussing some of the challenges in the field and the hurdles that need to be overcome in order to improve the efficacy of MSC therapy in COPD \[[@CR51]\].

Standardization of MSC Cell Culture Conditions {#Sec100}
----------------------------------------------

MSCs are known to be a heterogeneous cell population \[[@CR52], [@CR53]\], containing subpopulations that have been demonstrated to be functionally different from each other \[[@CR54], [@CR55]\]. Many of the phenotypic and functional differences depend on differences in culture conditions, individual donors, the harvest site, and the tissue source \[[@CR56]--[@CR59]\]. This makes it difficult to compare results between different studies, both preclinical and clinical, and importantly it hinders progression in the field. Efforts should therefore be concentrated on developing standardized MSC isolation methods and culture conditions. In 2006, the International Society for Cellular Therapy published a position paper in order to address this issue. In this article, they defined minimal suggested criteria for cultured human MSCs \[[@CR60]\]. Since this position paper by Dominici et al. was published it has been updated once in 2012 \[[@CR6]\], but the MSC field has advanced and today MSCs are isolated from different organs and tissues and therefore these minimal criteria urgently need to be modified and updated.

To date, bone marrow-derived MSCs are the most widely investigated, but preclinical studies have demonstrated that MSCs with immune-regulatory and regenerative properties can be isolated from other tissues such as adipose tissue, umbilical cord, and lung \[[@CR58], [@CR61]--[@CR66]\]. A large body of data demonstrates that MSCs execute their therapeutic effects through a spectrum of paracrine activities, and interestingly preclinical data suggest that MSCs isolated from different tissues have different secretome profiles \[[@CR57], [@CR67]\]. It is also important to realize that primary MSCs change phenotype when they are isolated from their native tissue and plated on a plastic culture dish \[[@CR56]\]. The bona-fide MSC, which are thought to be small and quiescent, noncycling cells in vivo, changes phenotype into a spindle-shaped and active proliferating and secretory cell in culture \[[@CR56], [@CR68]\]. At early passages, MSCs have a high proliferation rate but as their time in culture progresses their proliferation rate declines and they finally enter a senescence stage \[[@CR69]--[@CR71]\]. Also the morphology is changed during culture expansion, MSCs in early passages have a thin spindle-shaped morphology, but at higher passages MSCs tend to become larger and more flattened cells with an irregular shape \[[@CR56], [@CR70]\]. Moreover, MSCs have been reported to accumulate DNA damage during in vitro expansion, which could potentially lead to tumorigenesis upon implantation \[[@CR72], [@CR73]\]. Importantly, tumor development was not observed in any of the clinical studies using MSC as treatment for COPD and/or emphysema patients, although longer follow-up is necessary \[[@CR29]--[@CR32]\].

Furthermore, the biological properties of MSCs can also be strongly influenced by the cell culture medium. Cell culture media are often supplemented with serum, and most often fetal bovine serum (FBS) is used. The use of FBS has several disadvantages, especially in clinical settings. First, the possibility of contamination with pathogens such as prions and viruses and the potential immune reaction to bovine proteins. Second, lot-to-lot variation between different FBS batches might induce differences in MSC behavior such as proliferation rates and differentiation potential, and make it difficult to standardize methods and reproducibility of results \[[@CR56], [@CR74], [@CR75]\]. Human platelet lysate (HPL) is as an alternative to FBS in clinical settings. HPL has the advantages of containing non-animal products and therefore no risk of xenogeneic infections and immune rejection. On the other hand, HPL is a human product and has the potential to transmit human diseases such as hepatitis B and C, and human immune deficiency virus (HIV). In similarity with FBS, HPL also brings the disadvantage of having lot-to-lot variation \[[@CR75], [@CR76]\]. A third option would be to use serum-free cell or synthetic culture media. These media are highly promising, but more studies are needed in order to have evaluate their utility for producing clinical grade-MSCs. Recently, Lensch et al. demonstrated that MSCs had a higher proliferation rate when growing in xeno-free medium which resulted in a greater viable cell yield compared to standard FBS containing culture medium \[[@CR77]\]. Nevertheless, further studies are needed in order to evaluate if the in vivo biological properties of MSC are altered when expanded in the in vitro setting.

Another factor that may influence the biological function of MSCs is the freezing and thawing of cells before administrated to patients. The current model for allogeneic MSC use is to expand cells on plastic culture dishes following harvest and isolation from bone marrow or other source and cryopreserve the cells until usage. When it is time for administration, cells are thawed, washed, and directly administered to the patients most commonly through intravenous infusions \[[@CR78]\]. However, a number of studies have demonstrated that MSCs that have been freeze-thawed have impaired functional properties. Francois et al. reported that cryopreserved MSCs had impaired immunosuppressive properties \[[@CR78]\]. In accordance with these results, Moll et al. published an article where they demonstrated that freeze-thawed MSCs had a reduced responsiveness to proinflammatory stimuli and an impaired production of anti-inflammatory mediators \[[@CR79]\]. Minor effects on gene expression of freeze-thawed MSCs compared to continuously cultured MSCs have been observed. However, the alterations in gene expression between different donors were larger than the effects of cryopreservation \[[@CR80]\]. Although there is a practical need for expanding and cryo-banking cells for therapeutic use \[[@CR79]\], most preclinical studies have been performed using log phase of growth MSC. There are studies, some of them discussed above, which demonstrated that freeze-thawing procedure alters the biological properties of MSC. Francois et al. found that during the thawing process a heat-shock stress response was initiated that was associated with the impaired immunosuppressive properties of MSC. Interestingly, this response was reversible and cells were recovered after 24 h of culture \[[@CR78]\]. These results imply that cryopreservation and banking of cells might be possible, as long as the cells are allowed to recover in culture before use. The study by Cruz et al. further supports the potential of using freeze-thawed cells for clinical trials. In this study, the authors compared the therapeutic effect of continuously cultured versus freshly thawed bone marrow-derived MSCs in an *Aspergillus* hyphal extract (AHE) exposed asthma mouse model, and found no difference in therapeutic effect between the two groups \[[@CR81]\].

Utilizing plastic culture dishes are by far the most traditional way of cultivating and expanding MSC; however, alternative culture systems have been developed that might mimic the in vivo situation more compared to the more traditional 2D cultivation on plastic. The use of alternative three-dimensional cell culture systems can hopefully contribute to narrowing the gap between preclinical and clinical research. Different groups have studied the possibility to grow MSCs on plastic culture dishes coated with extracellular matrix molecules (ECM) such as collagen and fibronectin \[[@CR82], [@CR83]\]. ECM is a three-dimensional network composed of noncellular structures that play an important role within the lung, not only by providing structural support and adding stability but also as a bioactive environment that can influence cellular responses \[[@CR84]\]. Engler et al. demonstrated that changing the elasticity of the ECM that MSCs were grown on significantly affected the MSC phenotype. MSCs grown on a stiffer ECM differentiated towards the osteoblast lineage, whereas MSCs grown on a softer ECM differentiated towards the adipocyte lineage \[[@CR85]\]. The MSC differentiation potential could also be altered by changing the cross-linking of the collagen fibers \[[@CR86]\]. In addition, modifications of the geometric shape, cell density, and cell size have been implicated in the differentiation potential of MSC \[[@CR87], [@CR88]\]. Interestingly, McMurray et al. developed a nanoscale surface that maintained the phenotype and multilineage potential of long-term cultured MSCs \[[@CR89]\]. How the ECM environment affects the MSC therapeutic behavior, especially in a fibrotic or emphysematous COPD lung, is currently a largely untouched area that will most likely play a pivotal role in the development of successful MSC-based therapies.

A different approach of the three-dimensional cultures is the usage of the hanging drop model. In conformity with primary MSCs, culturing MSCs using the hanging drop method resulted in nondividing cells \[[@CR90]\], but an increased potential to differentiate towards osteoblast and adipocyte lineages was also demonstrated \[[@CR91]\]. Another strategy that has been used for MSC expansion relies on culturing MSCs in 3D scaffolds (decellularized lung tissue or synthetic scaffolds) \[[@CR92]--[@CR94]\]. In this system, cultivation on a plastic surface could be avoided, but a perfusion-based bioreactor system is required \[[@CR56]\]. Studies have shown that MSCs cultured in lung ECM hydrogels have enhanced viability and increased expression of Sox2 and Oct4 compared to cells grown on plastic \[[@CR95]\]. Furthermore, changes in secretion of cytokines including IL-1Ra, VEGF, G-CSF, FGF, and HGF have been demonstrated in MSCs grown in 3D culture compared to 2D \[[@CR96], [@CR97]\]. Taken together, the traditional way of cultivating MSCs as monolayer on a plastic surface may result in MSCs with a different phenotype compared to MSCs expanded in three-dimensional culture systems. However, whether cultivating MSCs on ECM coating, in scaffolds, or in hanging drops increases the beneficial effects when used for clinical settings remains to be evaluated and further studies are needed.

It is well known that oxygen levels can affect cell functions, such as differentiation, cytokine production, and proliferation \[[@CR98]--[@CR101]\]. Furthermore, it is also known that different adult tissues experience a wide range of oxygen levels \[[@CR102]\] and that severe pathological inflammation can cause hypoxia, reduced pH, and oxidative stress \[[@CR103], [@CR104]\]. Nevertheless, MSCs tend to be cultured at atmospheric oxygen levels (20--21% O~2~) which do not reflect the microenvironment they normally reside in, or the microenvironment they will encounter when administered into the diseased lung \[[@CR102]\]. Culturing MSCs at oxygen levels that more closely represent their in vivo situation have a huge impact on MSC behaviors. Lennon et al. observed that MSCs grown at lower oxygen levels had a greater number of colony-forming cells and proliferated at a higher rate compared to MSCs grown at higher oxygen levels. Also, Lennon et al. demonstrated that MSCs cultured at 5% oxygen formed more bone structures in vivo, compared to MSCs grown in 20% oxygen \[[@CR105]\]. Moreover, adipose-derived MSCs grown at low oxygen levels, secreted higher levels of cytokines such as VEGF and FGF compared to cells cultured at 20% oxygen \[[@CR102]\]. Combining the low oxygen condition with growing the MSCs in 3D cultures has been shown to increase the expression of pluripotent genes such as Oct-4, Sox-2, Nanog, and Rex-1 compared to control \[[@CR99], [@CR106]\]. Beegle et al. reported that MSCs pretreated with hypoxia before administration enhanced survival rate and cell retention compared to cell grown at 20% oxygen. Taken together, these studies emphasize the importance of understanding the effects of differences in protocols, culture conditions, and oxygen levels in the context of culturing MSCs for clinical trials for COPD where you have gas-exchange impairment, active immune response, and inflammation.

The Exact Mode of Action of MSC In Vivo Needs to Be Discovered {#Sec101}
--------------------------------------------------------------

Despite an enormous interest in using MSCs for clinical settings, the exact in vivo function is not understood, especially not within the lung. A compelling amount of data now points towards that MSCs act by paracrine mechanisms rather than through engraftment \[[@CR51], [@CR107]--[@CR116]\]. Tracking studies of intravenous injected MSCs reveal that most of the injected cells disappear after 24 h \[[@CR33], [@CR46], [@CR110], [@CR117]\], and since MSCs do not engraft it is unlikely that MSCs can remodel injured tissue by differentiating into other cell types. The mechanisms by which MSCs are the most likely to be involved in COPD and emphysema are discussed below.

Immunomodulation through paracrine actions is one of the main mechanisms of actions of MSCs and involves both the innate and the adaptive immune system \[[@CR118]--[@CR131]\] (Fig. [6.2](#Fig2){ref-type="fig"}). These effects include inhibition of T-cell \[[@CR120], [@CR121]\] and B-cell proliferation \[[@CR127]\], macrophage polarization \[[@CR119]\], and differentiation of T-cells towards T-regulatory cells \[[@CR132]--[@CR134]\]. The paracrine actions have been associated with several mediators such as hepatocyte growth factor (HGF), transforming growth factor beta (TGF-β), prostaglandin (PGE2), IL-10, IFN-gamma, TNF-stimulated gene 6 (TSG6), and indoleamine 2, 3-dioxygenase (IDO) \[[@CR115], [@CR118], [@CR119], [@CR135], [@CR136]\]. In addition to the paracrine immunomodulatory effects, MSCs might activate the immune system by recognition of the immune cells. As mentioned, MSCs are rapidly cleared from the lung after infusion, which was recently demonstrated to be mainly through phagocytosis by monocytes \[[@CR137]\]. The recognition of MSCs by monocytes results in a polarization of monocytes/macrophages towards an immunosuppressive phenotype that results in an immunomodulatory response \[[@CR137], [@CR138]\]. Similar results have also been demonstrated with heat-inactivated MSCs, suggesting that MSCs also can act in a passive immunomodulatory manner \[[@CR139]\]. However the potency of apoptotic MSCs are controversial, apoptotic MSCs have been demonstrated to be completely ineffective when injected intravenously in mice \[[@CR140]\]. MSC are also known to secrete antimicrobial proteins and polypeptides that are molecules responsible for bacterial killing. MSCs secrete the antimicrobial peptide, LL-37, following *Eschericia coli.* stimulation, which was subsequently found to be responsible for the antimicrobial activity in a model of *E. coli* Pneumonia \[[@CR141]\]. In addition to its antimicrobial activities, LL-37 can also play an important role in inflammatory and immune modulatory actions \[[@CR141], [@CR142]\].Fig. 6.2A schematic illustration describing the potential immunomodulatory functions of MSCs. Abbreviations: *EVs* extracellular vesicles, *MSCs* mesenchymal stromal cell, *DC* dendritic cell, *NK* natural killer cell, *Mac* macrophage

A growing body of data suggests that MSCs can form links with other cells, and that they have the potential to transfer components such as mitochondria \[[@CR143]--[@CR146]\]. Through mitochondrial transfer MSC have been demonstrated to be able to rescue epithelial cells with defective mitochondria \[[@CR144]\]. The mitochondria transfer is thought to be via direct transfer by microtubules and tunneling nanotubes (TNT) \[[@CR144], [@CR147]\]. MSCs can also transfer mitochondria to macrophages resulting in an increased phagocytic activity \[[@CR148]\]. Mitochondrial biogenesis is regulated by extracellular stimuli \[[@CR149]\] and several lung diseases are associated with impaired mitochondrial biogenesis and dysfunctional mitochondria \[[@CR150], [@CR151]\]. However, beyond the mitochondria-derived reactive oxygen species (ROS), the contribution of mitochondria in the development of COPD is still under investigation \[[@CR152]\]. In addition to mitochondria transfer through microtubules and TNT, mitochondria can also be transported via extracellular vesicles (EV) \[[@CR144], [@CR153]--[@CR155]\]. It is also becoming increasingly clear that MSC-derived EVs can influence the behavior of surrounding inflammatory and structural cells. For example, EVs released from MSCs can stimulate bronchial epithelial cells and alveolar cells to secrete proinflammatory cytokines \[[@CR156], [@CR157]\]. Furthermore, MSC-derived EVs suppress the potential of lung fibroblasts to differentiate towards myofibroblasts \[[@CR158]\]. It is not only mitochondria that could be transferred by MSC-derived EVs, also other components such as microRNA, proteins, lipids, DNA, and mRNA \[[@CR159], [@CR160]\]. EVs are taken up by other cells, and EVs derived from MSCs have been demonstrated to impact immune cells. EVs isolated from IL-beta pretreated MSCs induced macrophage polarization towards the anti-inflammatory phenotype (M2) \[[@CR161]\]. MSC-derived EVs have also been associated with inhibition of T-cell proliferation, inducing apoptosis of activated T-cells and promotion of regulatory T-cells \[[@CR162]\]. MSC-derived EVs have been tested in experimental COPD models, but further studies are needed \[[@CR163]\].

The Beneficial Outcome Needs to Be Significantly Increased {#Sec102}
----------------------------------------------------------

It is now widely accepted that, following in vivo delivery, culture-derived MSCs respond to the microenvironment they encounter, which in COPD and emphysema could encompass everything from massive inflammatory environment to emphysematous tissue destruction. Therefore, it is important to consider several important aspects of the MSC preparation and administration used today.

The route by which MSCs are delivered into the patients most likely plays an important role in the MSC potential function. Despite the fact that several clinical trials has been performed using MSCs for severe lung disorders \[[@CR29]--[@CR32], [@CR164]--[@CR168]\], the best route of administration have not been determined. In preclinical studies, two main administration routes have been evaluated: systemic administration \[[@CR34], [@CR41], [@CR43], [@CR45], [@CR47], [@CR48], [@CR50], [@CR169], [@CR170]\] and local administration \[[@CR39], [@CR41]--[@CR43], [@CR171], [@CR172]\]. COPD is a systemic disease and therefore systemic administration might be better suitable for these patients. In addition, systemic administration is less invasive and has less contamination risks compared to local administration \[[@CR51]\]. Not only has the route of administration been different in the different studies conducted to date but also the number of cells administered with each injection and whether single or multiple injections were administered during the trial. According to Antunes et al. a wide range of MSC doses in preclinical settings have been used, from 10^4^ up to 6 × 10^6^ \[[@CR51]\]. So far, bone marrow-derived MSCs are the most frequently used cell source for MSC-treatments, especially when used in human clinical trials. However, MSCs derived from other sources such as adipose-derived, umbilical cord-derived, lung-derived, and amniotic fluid-derived MSCs have been evaluated for treatment of COPD/emphysema models \[[@CR36], [@CR41], [@CR50], [@CR172]\].

Since it is known that the environment affects MSC function and viability, several preconditioning strategies have been tested. Some researchers have been focusing on the effect of the inflammatory environment and the cytokines that may be encountered in the diseased lung \[[@CR124], [@CR173]--[@CR179]\]. Krampera et al. reported that MSCs stimulated with IFN-gamma, increased the levels of IDO produced and secreted by MSCs, leading to an increased suppressive effect on T-lymphocyte proliferation. Moreover, the authors were able to demonstrate that the inhibitory effects of MSCs on T-lymphocyte proliferation were completely abolished when adding an IFN-gamma blocking antibody to the culture system \[[@CR124]\]. In an IFN-gamma knock out mouse model, Polchert et al. were able to demonstrate that endogenous IFN-gamma was required to initiate MSC efficacy. However, after pretreatment of MSCs with high doses of IFN-gamma they immediately became active \[[@CR173]\]. Also pre-stimulating MSCs with a combination of inflammatory cytokines has been explored \[[@CR174], [@CR175]\]. Another interesting approach to mimic the microenvironment is to utilize patient samples such as serum and bronchoalveolar lavage (BAL) fluid from patients and pre-stimulate cells with such prior to the administration \[[@CR180], [@CR181]\]. Moreover, attempts to improve the beneficial effects of MSCs have utilized treatment with the toll-like receptor-3 ligand (poly(I:C)). The authors found that MSCs pretreated with poly(I:C) had improved immunosuppressive properties, an effect that was inhibited by addition of the microRNA miR-143 \[[@CR182]\]. In addition to the inflammatory environment, others have studied the effect of pretreating MSCs with hypoxia and nutrient deficiency. During culture under hypoxic conditions, MSCs have been shown to have decreased expression of senescence-associated beta-galactosidase and an increase in the expression of anti-apoptotic proteins such as Bcl-2 and Bcl-xL \[[@CR183], [@CR184]\]. By exposing MSCs to hypoxia the hypothesis is that the cells will adapt to the ischemic environment with oxidative stress, an environment they likely will encounter in the COPD lung. This might potentially enhance the time that MSCs can survive and exert their therapeutic paracrine actions in the recipient lung.

A different way of increasing the therapeutic effect by MSCs is to genetically manipulate the cells prior to administration \[[@CR185]--[@CR187]\]. For example, Jiang et al. demonstrated that after co-overexpressing the genes Ang-1 and Akt in MSCs, an increased cell survival and improved angiomyogenesis was observed in an experimental model of acute myocardial infarction \[[@CR188]\]. In lung, MSCs overexpressing Ang-1 have been demonstrated to more potently decrease LPS-induced pulmonary inflammation and proinflammatory cytokine release into the BAL fluid \[[@CR189]\]. In another study by McGinley et al., overexpression of heat shock protein 27 (HSP27) in MSCs led to decreased apoptosis and improved cardiac function \[[@CR190]\]. Overexpression of manganese superoxide dismutase in adipose-derived MSCs, a gene strongly upregulated during hypoxia, increased the time that the MSCs were detectable in a matrigel plug implanted into a mouse model \[[@CR191]\]. Moreover, He et al. transduced MSCs with angiotensin-converting enzyme 2 (ACE2), an enzyme that degrades angiotensin II and had previously been demonstrated to have a protective role against acute lung injury. The ACE2-transduced MSCs were demonstrated to reduce pulmonary vascular permeability, normalize the expression of eNOS, and improve the endothelial barrier integrity, when infused into an ALI-mouse model. Furthermore, the ACE2 overexpressing MSCs also displayed an improvement in the suppression of the inflammatory response \[[@CR192]\].

Combination of different treatments could be another approach to enhance MSC efficacy. This approach was used in two of the clinical trials discussed above. Stolk et al. combined MSC treatment with lung volume reduction surgery and de Oliveira et al. with a one-way endobronchial valve insertion \[[@CR31], [@CR32]\]. An alternative could be to pretreat the recipient tissue with pharmacological drugs in order to make the recipient site more accessible to the infused cells \[[@CR104], [@CR193]--[@CR195]\]. In a cardiac disease model, pharmacological pretreatment of a vasodilator drug in the recipient site of transplantation resulted in an enhanced delivery of MSCs \[[@CR193]\]. In a clinical trial using MSCs for treatment of chronic heart failure, the administration site was treated with a shock wave prior to the administration of the cells. In the group receiving both the shock wave pretreatment and the MSC infusion, the overall occurrence of major adverse cardiac events were significantly decreased compared to the control groups \[[@CR194]\].These are all important observations for potential cell-based therapies for lung diseases and should be investigated further.

Is COPD the Best Disease to Treat with MSC-Based Cell Therapy and How Do We Foresee Which Patients Will Respond to the Treatment? {#Sec109}
---------------------------------------------------------------------------------------------------------------------------------

The lack of translating the encouraging preclinical data into clinically relevant effects in patients with COPD and emphysema brings up the following question: is COPD the most suitable pulmonary disease for MSC-based treatment? The animal models of COPD and emphysema used in the preclinical studies were optimized to detect the maximum therapeutic effects \[[@CR196]\], and might therefore not reflect the in vivo situation that MSCs encounter when infused into patients with COPD and/or emphysema. COPD is characterized by tissue damage, structural changes, and inflammation, and as mentioned it is a heterogeneous disease with different degrees of fibrosis and emphysema \[[@CR197]\]. COPD patients with different phenotypes might respond differently to MSC administration \[[@CR198]\], and choosing patients that are more likely to respond to the treatment could be one way to improve the clinical outcome. Another possible way to improve the outcome could be the timing of the treatment. In animal studies, MSCs are frequently administered to the animals in close proximity to the induction of the disease \[[@CR42], [@CR48], [@CR50], [@CR172]\] or even at the same time or prior to the disease induction \[[@CR43], [@CR47]\]. Based on these preclinical findings, MSCs might be more beneficial earlier in the disease than in later stages of the disease. However, COPD patients tend not to seek medical attention in early stage of the disease \[[@CR199]\]. One way to foresee which patients would most likely respond to the treatment could be to develop in vitro potency assays. Even if it is widely accepted that the therapeutic effect of MSCs is mainly mediated by paracrine effects, the exact mechanism of action is not determined. This makes it difficult to develop one single analytic or biological assay, and most likely, a combination of evaluating different mechanisms would be needed \[[@CR200], [@CR201]\]. Another potential way would be to develop biomarkers to indicate which patients have an active disease and therefore might benefit more from a MSC-based therapy. To date, several potential biomarkers, including circulating fragments of ECM proteins, have been shown to be increased in COPD patients with an active disease e.g. in relation to acute exacerbations \[[@CR202]--[@CR204]\]. Finally, Broekman et al. suggested that in addition to the optimization of MSC-treatment and potency assays, challenges such as improved outcome parameters needs to be addressed \[[@CR196]\].

Stem Cell Tourism: A Growing Problem for the Field {#Sec9}
==================================================

In parallel with the growing interest of cell-based therapies for COPD and other lung diseases, an increased market for commercial stem cell therapies has developed both in the USA and globally \[[@CR205]\]. This very unfortunate and problematic outcome might partly be due to an increased visibility to desperate patients through the internet and open social media channels \[[@CR206]\]. These unproven and often unsafe stem cell treatments can create a situation in which desperate patients easily can be misled into participating in very expensive treatments, which are not covered by insurance. Furthermore, the providers at the stem cell clinics often fail to prove safety and efficacy of their treatments failing to fulfill recognized biological and medical standards, exposing the patients to unnecessary risks and leaving the patient and their family with dashed hopes \[[@CR205], [@CR207]\]. These stem cell clinics have the potential to harm even more patients and their families, as well as bring the field into disrepute and hamper the progression of safe and effective MSC-based therapies. Therefore, organizations such as the International Society for Stem Cell Research (ISSCR) and the International Society for Cell and Gene Therapies (ISCT) have taken stances against these unethical cell-therapy clinics. Also, the Food and Drug Administration (FDA) is beginning to take actions against the stem cell tourism \[[@CR205], [@CR208]\]. In a review by Dominici et al., the authors discuss the importance of having proper communication between different players such as medical doctors, industry, patient organizations, and patients, in order to enhance credibility and patient welfare \[[@CR205]\]. In an attempt to begin proactively addressing this issue, the American Thoracic Society (ATS) Respiratory Cell and Molecular Biology Assembly Stem Cell Working Group posted a statement online and several other related publications \[[@CR207], [@CR209]--[@CR212]\]. This statement will help to translate new scientific findings into patient education in an unbiased way and to make the public aware of the limitations and potential risks associated with such therapeutic approaches \[[@CR209], [@CR212]\]. However, it is not only the patients that need education, many pulmonologists are also not familiar with the stem cell field, and the ATS Respiratory Cell and Molecular Biology Assembly Stem Cell Working Group has developed educational resources for this audience also \[[@CR207]\].

Conclusions {#Sec10}
===========

MSC-based therapy for treatment of COPD and emphysema has demonstrated promising results in animal models; however, this has not translated into clinically relevant effects in patients to date. Current clinical trials have failed to demonstrate efficacy and improved lung function, but importantly they have uniformly demonstrated the MSC administration to be safe. The challenges ahead for this field are to standardize the isolation and culture conditions in order to have a cell product with high quality and reproducibility, to select the proper subpopulation of patients that is most likely to respond to the cell treatment, to develop appropriate potency assays, and to improve or develop new methods to measure outcomes. Furthermore, the usage of cell-free products such as EVs and conditioned medium, or pretreating MSCs prior to administration has demonstrated promising results. However, there is still a long way to go and many challenges are ahead before we have an optimal MSC-based treatment for patients with COPD and emphysema.
